查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853747

疫苗輸送裝置市場（按裝置類型、給藥途徑、最終用戶和產品形式分類）－全球預測，2025-2032年

Vaccine Delivery Devices Market by Device Type, Administration Route, End User, Product Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，疫苗輸送設備市場規模將達到 172.5 億美元，複合年成長率為 10.74%。

關鍵市場統計數據
基準年 2024 76.2億美元
預計年份：2025年 84.3億美元
預測年份 2032 172.5億美元
複合年成長率 (%) 10.74%

疫苗輸送裝置的多面向策略方向，重點在於臨床需求、工程發展、供應鏈複雜性和數位化整合。

疫苗輸送裝置領域處於臨床需求、技術創新和複雜法律規範交會的交匯點。近年來，疫苗輸送裝置已從純粹的機械式一次性裝置轉向整合系統，後者兼具人體工學、互聯性、低溫運輸相容性和用戶安全性等優點。這一轉變的驅動力源於不斷擴大的免疫接種計劃和日益複雜的治療性生技藥品，後者對劑量精準、低溫運輸完整性和依從性監測提出了更高的要求。

臨床相關人員和採購團隊正在適應新的環境，此時醫療器材的選擇不再僅取決於單價，而是要綜合考慮總管理成本、病患依從性和生命週期安全性。製造商正透過投資可製造性設計、人因工程以及支持快速臨床應用的監管策略來應對這一變化。同時，醫療服務提供者需要能夠滿足各種給藥途徑和臨床環境需求的醫療器械，從高通量醫院疫苗接種診所到慢性病居家護理，都能滿足這些需求。

鑑於市面上設備種類繁多，從自動注射器和輸液泵到無針注射器和預填充式注射器，相關人員必須權衡各種因素，例如易用性、無菌保證、與藥品劑型的兼容性以及環境影響。這些考量因素正日益與劑量追蹤、依從性計畫的連結性以及與電子健康記錄的互通性等數位化功能一同被納入考量。隨著市場的成熟，能否將設備選擇與臨床通訊協定、供應鏈實際情況和患者行為相匹配，將成為成功部署的關鍵因素。

數位連接、人性化的安全、模組化製造、監管清晰和供應鏈韌性等因素的匯聚將改變疫苗輸送裝置的格局。

多重變革正在改變疫苗接種設備的設計、製造、監管和應用方式。首先，數位化整合和連網型設備的成熟正在改變人們對接種後監測、依從性分析和遠端臨床監測的期望。這一趨勢不僅限於基本的連接，還包括安全的數據處理、設備認證以及分析輸出，這些輸出都能為個別患者護理和人群層面的疫苗接種策略提供資訊。

其次，人們重新關注以人性化的設計和安全，這促使他們偏好能夠降低針刺風險且易於非專業人員操作的醫療器材。這加速了人們對無針技術、安全設計的注射器以及在壓力下也能直覺操作的自動注射器的興趣。第三，生產策略正轉向模組化、靈活的平台，以適應多種器械規格和配方類型，從而能夠快速回應不斷湧現的需求。

第四，法規環境正朝著更明確的方向發展，包括對組合藥物、連網型設備的網路安全以及支援上市後監測的真實世界證據等方面的明確要求。這種監管的清晰性迫使製造商在研發過程的早期階段就納入合規性考量。第五，供應鏈韌性和近岸外包日益受到重視，企業正在重新評估供應商集中度、組件採購和滅菌能力，以降低地緣政治和物流風險。這些轉變正在形成一個格局：技術能力、監管前瞻性和供應鏈靈活性將決定哪些產品能夠獲得持續的臨床應用。

評估2025年關稅如何改變了整個生態系統的供應鏈採購決策、採購架構和設備開發重點。

2025年起對美國貿易徵收的關稅，對製造商、供應商和醫療保健機構產生了一系列累積影響。這些關稅提高了許多醫療器材類別中使用的進口零件的相對成本，直接影響了籌資策略，並引發了對全球供應商基礎的重新評估。對於依賴國際採購的精密模塑塑膠零件、電子感測器、消毒服務等的醫療設備而言，關稅負擔加速了關於本地生產或雙重採購安排的討論。

這些趨勢對嚴重依賴一次性用品的供應鏈影響尤其顯著，因為重複採購會持續增加成本。製造商和醫療保健系統必須權衡短期價格上漲與長期受益於本土生產能力（例如降低物流風險和提高供應連續性）之間的利弊。在產品開發方面，不斷上漲的零件成本迫使企業進行成本效益更高的設計變更，在某些情況下，甚至需要簡化產品，以在確保安全性和合規性的同時，保護淨利率。

採購團隊正在調整合約結構和對沖策略以降低波動性。同時，製造商正與一級供應商更緊密地合作，尋找既能降低成本又不影響無菌保證或性能的途徑。此外，有證據表明，醫療器材製造商與製劑合作夥伴之間的合作日益密切，旨在最佳化器械與藥物的兼容性並降低系統總成本。因此，關稅的累積效應正在加速供應鏈多元化、生產在地化以及器械設計選擇與採購實際情況更加緊密結合的現有趨勢。

從設備類型、給藥途徑、最終用戶環境和製劑形式等方面進行詳細的觀點，將有助於策略定位。

深入了解市場區隔對於使產品策略與臨床和商業性實際情況相符至關重要。從器械類型來看，市場包括自動注射器、輸液幫浦、噴射注射器、無針注射器、注射筆、預填充式注射器、注射器式泵和容積式泵，其中容積式泵又可進一步細分為門診型和落地式，以適應不同的護理環境和給藥量。

噴射注射器根據其多用途噴嘴結構和一次性噴嘴形式進行區分，而無針注射器則可用於輸送液體和粉末。筆式注射器有一次性使用和可重複使用兩種版本，即使是可重複使用版本，也分為電子式和機械式，在劑量精度和整合性方面各有不同。預填充式注射器有玻璃和塑膠兩種材質，其中塑膠材質又分為外置針和內置針兩種。安全注射器包含主動和被動安全功能，旨在減少銳器傷，並滿足職業安全要求。

給藥途徑是細分市場的重要維度，涵蓋皮內、肌肉內、靜脈、黏膜和皮下給藥途徑。黏膜給藥途徑又可細分為鼻腔和口腔途徑，每種途徑都有其自身的製劑和設備介面方面的挑戰。最終用戶包括門診中心、診所、家庭醫療保健機構和醫院。在診所內部，基層醫療診所和專科診所的需求在吞吐量、人員專業水平和治療重點方面有所不同。產品劑型是另一個關鍵的區分因素，液體製劑和冷凍乾燥製劑在處理、復溶和設備相容性方面有不同的要求。液體製劑和冷凍乾燥製劑均可採用多劑量或單劑量管瓶包裝，這些選擇會影響設備的選擇、廢棄物管理和低溫運輸物流。因此，制定一個整合的細分策略，將設備類型、給藥途徑、最終用戶環境和產品類型相匹配，對於使解決方案的功能與臨床工作流程和採購限制相匹配至關重要。

美洲、歐洲、中東和非洲以及亞太地區的區域差異和採用動態會影響設備選擇、製造和採購。

區域動態持續以不同的方式影響技術應用、監管路徑和供應商關係。在美洲，採購模式和大規模疫苗接種計畫推動了對兼顧單位效率和安全性的設備的需求，同時，能夠與疫苗接種登記系統和電子健康記錄整合的連網型設備也越來越受到青睞。此外，該地區也正在加速推動近岸外包和擴大生產規模的討論，以應對全球供應鏈中斷的風險。

在歐洲、中東和非洲地區，監管趨同和對病人安全的重視推動了人們對安全型注射器和無針注射器的興趣，而採購能力的差異則導致了不同的採用率和設備偏好。數位化整合和全生命週期服務正在成為該地區高所得市場的差異化因素，而在資源匱乏的環境中，簡便性、穩健性和低溫運輸效率仍然至關重要。

亞太地區是一個多元化的區域，擁有蓬勃發展的工業能力、雄心勃勃的國內製造業以及各具特色的管理體制。該地區的多個市場正在擴大醫療設備和藥品的本地生產能力，並且對能夠支持大規模疫苗接種宣傳活動的低成本拋棄式和創新無針技術表現出濃厚的興趣。由於各地區在臨床實務、報銷模式和供應鏈架構方面的差異，採用一刀切的醫療器材策略不太可能成功。

企業平台策略、策略聯盟、監理立場與服務模式如何重新定義設備製造商的競爭優勢

主要企業之間的競爭與合作正以多種可預見的方式塑造疫苗輸送裝置的發展。領先的製造商正投資於平台策略，使其能夠在多個治療領域擴展裝置功能，同時分攤研發和監管成本。裝置公司與生技藥品開發商之間的夥伴關係日益普遍，這反映出需要在研發早期檢驗裝置與藥物的兼容性，並設計整合的病患支援方案。

如果滅菌能力、組件供應和大規模組裝成為快速規模化生產的障礙，我們將看到供應端的整合和策略聯盟。同時，一些規模較小的創新者將推動細分領域的進步，例如無針技術、微劑量給藥和數位化依從性工具，而現有企業可能會選擇透過收購或授權進行整合。監管核准和許可途徑仍然是競爭的核心問題，那些能夠展現出強大的人體工學測試、網路安全保障和上市後證據生成的公司更容易獲得醫療保健系統的認可。

從設備即服務到包含訓練、維護和資料分析的全生命週期支援協議，服務模式正逐漸成為採購決策中的差異化因素。能夠將產品品質、可靠的供應和快速反應的服務相結合的公司，尤其是在營運連續性和臨床結果備受關注的市場中，更有可能佔據優勢地位。

醫療設備製造商和醫療保健提供者可採取切實可行的策略性舉措，以增強韌性、加速產品應用，並在醫療保健環境中創造持久價值。

產業領導者應採取多管齊下的策略，兼顧短期韌性和長期創新。首先，應實現供應商組合多元化，投資於關鍵零件的雙重採購，同時評估近岸外包機會，以降低關稅波動和物流中斷帶來的風險。其次，應優先發展模組化產品平台，以便快速重新配置一次性及可重複使用零件，並設計成與數位醫療生態系統互通性，從而提升臨床價值。

第三，在研發生命週期的早期階段融入監管策略和人因工程，可以降低產品上市時間風險，並有助於制定清晰的標籤和上市後監測計畫。第四，與製劑開發商建立夥伴關係，最佳化液體製劑和冷凍乾燥製劑的器械-藥物相容性，並使器械介面適應基層醫療機構、專科診所、醫院、門診中心和家庭醫療保健的實際需求。第五，考慮器械本身以外的服務，例如培訓、維護、數據分析和生命週期管理，以創建差異化的採購提案，從而降低整體管理成本並提高臨床依從性。

最後，要重視收集能夠展現產品在真實世界中的效能、安全性和使用者偏好的證據。真實世界試驗、可操作的可用性研究和註冊資料能夠加速支付方和醫療服務提供者的接受度。透過將產品設計與採購實際情況和臨床工作流程相結合，行業領導者可以減少推廣阻力，並為規模化發展鋪平道路。

透過綜合性的混合方法研究途徑檢驗研究結果，該方法結合了深度訪談、法規和專利審查、供應鏈圖譜繪製以及情境分析。

本研究整合了多種資料流，以得出可靠且基於證據的結論。主要研究包括對設備工程師、醫院和門診臨床負責人、採購負責人以及監管專家進行結構化訪談，以獲得有關設備性能、易用性和供應限制的實證見解。專家研討會和諮詢小組則為解讀臨床工作流程以及臨床醫生在為不同給藥途徑和產品形式選擇設備時面臨的實際權衡提供了資訊。

二級研究涵蓋了官方監管文件、指導文件、專利文件、製造商技術規範以及同行評審的臨床研究，以檢驗設計聲明和安全性概況。供應鏈圖譜結合了供應商揭露資訊、物流數據和貿易流量分析，以識別集中風險和潛在的恢復策略。在適當情況下，也審查了人因工程和可用性測試報告，以評估使用者出錯風險和培訓需求。

分析方法包括：將質性調查結果與文獻證據進行交叉檢驗；對供應鏈應對關稅和中斷事件的反應進行情境壓力測試；以及對技術採納促進因素進行主題綜合分析。製造商的說法與獨立的臨床和採購觀點進行三角驗證，以提供平衡且可操作的見解。透過尋找關鍵論斷的多個資訊來源，並記錄資料匱乏且需要謹慎解讀的領域，來減輕研究的限制。

本文綜合闡述了各項策略要務，闡明了技術、監管、市場區隔和供應鏈韌性如何協同運作，才能提供有效的疫苗接種解決方案。

疫苗輸送裝置領域正經歷著一場由技術進步、不斷變化的監管環境以及人們對安全性和供應穩定性的日益成長的期望所驅動的變革時期。如今，衡量裝置創新的標準不再僅限於單一產品的特性，而是其能否在臨床工作流程、依從性和整體系統可靠性方面帶來可衡量的改進。供應鏈和貿易動態正在加速策略轉型，例如供應商多元化、模組化生產方式以及重新聚焦於能夠帶來營運優勢的在地化生產能力。

按設備類型、給藥途徑、最終用戶環境、製劑形式等進行細分仍然至關重要，以便將解決方案的特性與實際應用場景相匹配。區域差異凸顯了製定適應性策略的必要性，這些策略應考慮採購機制、管理體制和基礎設施限制。將強大的產品工程與周密的監管規劃、以服務為導向的經營模式以及有針對性的證據生成相結合的公司，將最有利於確保產品的長期應用。未來的道路需要設計、製造和商業部門之間的協調行動，才能將前景看好的技術轉化為疫苗供應和公共衛生結果的永續改善。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 提高無針噴射注射器和微陣列貼片系統的臨床應用率，以提高病患依從性並降低浪費風險
  • 在團體疫苗接種過程中，整合物聯網智慧自動注射器，實現即時劑量追蹤和遠端患者監護。
  • 開發一種耐熱疫苗輸送裝置，因此無需低溫運輸即可在資源匱乏地區進行疫苗分發。
  • 溶解性微針貼片技術的進步有望使人們能夠在臨床環境之外進行無痛的自我疫苗接種。
  • 推出一款組合疫苗自動失效注射器，旨在最大限度地減少多劑量造成的交叉污染，並簡化疫苗接種程序。
  • 擴大模組化和預製灌裝和包裝平台，以加速疫情期間的疫苗生產反應。
  • 採用可生物分解、一次性使用且環保的注射器材料，以解決永續性和生物危害管理問題。
  • 監管協調舉措旨在統一全球創新疫苗輸送裝置和數位健康整合的核准途徑。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依設備類型分類的疫苗輸送設備市場

  • 自動注射器
    • 一次性自動注射器
    • 電子可重複使用自動注射器
    • 機械式可重複使用自動注射器
  • 點滴幫浦
    • 彈性體泵
    • 注射式幫浦
    • 容積式泵
      • 攜帶式容積泵
      • 落地式容積泵
  • 噴射注射器
    • 多用途噴嘴噴射注射器
    • 一次性噴嘴噴射注射器
  • 無針注射器
    • 液體噴射器
      • 電動液體噴射器
      • 氣基液體噴射器
      • 彈簧式液體噴射器
    • 粉末注射器
  • 筆式注射器
    • 一次性注射筆
    • 可重複使用的注射筆
      • 可重複使用的電子筆注射器
      • 機械式可重複使用注射筆
  • 預填充式注射器
    • 玻璃預填充式注射器
    • 塑膠預填充式注射器
      • 預填充式注射器，附外針頭
      • 一體式針頭預填充式注射器
  • 安全注射器
    • 主動安全注射器
    • 被動安全注射器

9. 依給藥途徑分類的疫苗輸送裝置市場

  • 皮內注射
  • 肌肉內注射
  • 靜脈注射
  • 黏膜遞送
    • 鼻腔給藥
    • 口服
  • 皮下注射

10. 依最終用戶分類的疫苗輸送裝置市場

  • 門診治療中心
  • 診所
    • 基層醫療診所
    • 專科診所
  • 家庭醫療保健
  • 醫院

11. 依產品類型分類的疫苗輸送裝置市場

  • 液體配方
    • 多劑量管瓶
    • 單劑量管瓶
  • 冷凍乾燥製劑
    • 多劑量管瓶
    • 單劑量管瓶

12. 各地區疫苗輸送裝置市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 按組別分類的疫苗輸送裝置市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國疫苗輸送裝置市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • West Pharmaceutical Services, Inc.
    • Becton, Dickinson and Company
    • SCHOTT AG
    • Gerresheimer AG
    • Stevanato Group SpA
    • Terumo Corporation
    • Nipro Corporation
    • Catalent, Inc.
    • Vetter Pharma International GmbH
    • Recipharm AB
Product Code: MRR-02026C4C8C99

The Vaccine Delivery Devices Market is projected to grow by USD 17.25 billion at a CAGR of 10.74% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.62 billion
Estimated Year [2025] USD 8.43 billion
Forecast Year [2032] USD 17.25 billion
CAGR (%) 10.74%

A strategic orientation to the multifaceted vaccine delivery device landscape highlighting clinical needs, engineering evolution, supply chain complexity, and digital integration

The vaccine delivery device field sits at the intersection of clinical need, engineering innovation, and complex regulatory oversight. Recent years have seen a shift from purely mechanical disposables toward integrated systems that combine ergonomics, connectivity, cold chain compatibility, and user safety. This evolution is driven by the dual pressures of expanding immunization programs and the increasing complexity of therapeutic biologics that demand precise dosing, cold chain integrity, and adherence monitoring.

Clinical stakeholders and procurement teams are adapting to an environment where device selection is no longer driven solely by unit cost but by total cost of administration, patient adherence, and lifecycle safety. Manufacturers are responding by investing in design for manufacturability, human factors engineering, and regulatory strategy to support quicker clinical adoption. Meanwhile, healthcare providers require devices that address a range of administration routes and site-of-care constraints, from high-throughput hospital vaccination clinics to home-based administration for chronic therapies.

Given the breadth of device types-from auto-injectors and infusion pumps to needle-free injectors and prefilled syringes-stakeholders must evaluate trade-offs across usability, sterility assurance, compatibility with formulation formats, and environmental footprint. These considerations are increasingly evaluated alongside digital features such as dose tracking, connectivity for adherence programs, and interoperability with electronic health records. As the market matures, the ability to align device selection with clinical protocols, supply chain realities, and patient behavior will be a key determinant of successful deployment.

Converging forces of digital connectivity, human-centered safety, modular manufacturing, regulatory clarity, and supply chain resilience transforming vaccine delivery device dynamics

Multiple transformative shifts are reshaping how vaccine delivery devices are designed, manufactured, regulated, and adopted. First, digital integration and the maturation of connected devices are changing expectations for post-administration monitoring, adherence analytics, and remote clinical oversight. This trend extends beyond basic connectivity to include secure data handling, device authentication, and analytics-ready outputs that inform both individual patient care and population-level immunization strategies.

Second, human-centered design and a renewed focus on safety have elevated preferences for devices that reduce needle-stick risk and improve ease-of-use for non-specialist administrators. This has accelerated interest in needle-free technologies, safety-engineered syringes, and auto-injectors that prioritize intuitive operation under stress. Third, manufacturing strategies are shifting toward modular and flexible platforms that can accommodate multiple device formats and formulation types, enabling faster configuration for emergent needs.

Fourth, regulatory environments are converging around clearer expectations for combination products, cybersecurity for connected devices, and real-world evidence to support post-market surveillance. This regulatory clarity is prompting manufacturers to embed compliance considerations earlier in the development process. Fifth, supply chain resilience and nearshoring are gaining prominence, with organizations re-evaluating supplier concentration, component sourcing, and sterilization capacity to reduce geopolitical and logistic risk. Together, these shifts are creating a landscape in which technological capability, regulatory foresight, and supply chain agility determine which products achieve durable clinical uptake.

Assessment of how tariff measures implemented in 2025 have reshaped supply chain sourcing decisions, procurement frameworks, and device development priorities across the ecosystem

The introduction of tariffs in 2025 affecting trade flows into and out of the United States has produced a set of cumulative impacts that ripple across manufacturers, suppliers, and healthcare providers. Tariff measures have increased the relative cost of imported components used in many device categories, creating immediate pressure on procurement strategies and inducing a re-evaluation of the global supplier base. For devices that rely on precision-molded plastic components, electronic sensors, or sterilization services sourced internationally, the tariff burden has accelerated conversations about local manufacturing or dual-sourcing arrangements.

This dynamic has particular implications for disposable-heavy supply chains where recurring purchases amplify the cost impact. Manufacturers and health systems have had to reconcile the trade-off between short-term price increases and the long-term benefits of onshore capacity such as reduced logistics risk and improved supply continuity. For product development, higher component costs have prompted design-for-cost reviews and, in some cases, product simplification to protect margins while preserving safety and regulatory compliance.

Procurement teams are adapting contract structures and hedging strategies to mitigate volatility, while manufacturers are engaging more closely with tier-one suppliers to identify cost-reduction pathways that do not compromise sterility assurance or performance. At the same time, there is evidence of increased collaboration between device makers and formulation partners to optimize device-drug compatibility and reduce total system costs. The cumulative effect of tariffs has therefore been to accelerate existing trends toward supply chain diversification, localized manufacturing, and closer alignment between device design choices and procurement realities.

In-depth segmentation perspective that connects device typologies, administration pathways, end-user environments, and formulation formats to inform strategic positioning

A granular understanding of segmentation is essential for aligning product strategy with clinical and commercial realities. When viewed through the lens of device type, the landscape comprises auto-injectors, infusion pumps, jet injectors, needle-free injectors, pen injectors, prefilled syringes, and safety syringes. Within auto-injectors, there are disposable devices as well as reusable platforms that divide into electronic and mechanical subtypes, each with distinct implications for lifecycle costs, training burden, and data capture. Infusion pumps span elastomeric, syringe-based, and volumetric approaches, with volumetric options further characterized by ambulatory and floor-mounted systems that serve different care settings and administration volumes.

Jet injectors differentiate between multi-use nozzle architectures and single-use nozzle formats, while needle-free injectors split into liquid and powder delivery modalities; liquid systems further segment into electric, gas-based, and spring-based mechanisms that entail varied power and maintenance considerations. Pen injectors offer disposable and reusable choices, and among reusables there is a split between electronic and mechanical innovators that alter dosing precision and integration potential. Prefilled syringes are available in glass or plastic constructions, with plastic variants subdividing into external needle and integrated needle configurations that influence ease-of-use and disposal practices. Safety syringes come in both active and passive safety implementations, each designed to reduce sharps injuries and support compliance with occupational safety requirements.

Administration route is a complementary axis of segmentation, encompassing intradermal, intramuscular, intravenous, mucosal, and subcutaneous approaches. Mucosal delivery further bifurcates into nasal and oral pathways, each presenting unique formulation and device interface challenges. End-user contexts include ambulatory care centers, clinics, home healthcare, and hospitals; within clinics, the needs of primary care and specialty clinics diverge based on throughput, staff expertise, and therapeutic focus. Product form is another critical discriminator, with liquid and lyophilized formulations presenting different handling, reconstitution, and device compatibility requirements. Both liquid and lyophilized families can be packaged in multi-dose or single-dose vials, and those choices influence device selection, waste management, and cold chain logistics. An integrated segmentation strategy that aligns device type, administration route, end-user setting, and product form is therefore essential to matching solution capabilities with clinical workflows and procurement constraints.

Regional contrasts and adoption dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence device selection, manufacturing, and procurement

Regional dynamics continue to shape technology adoption, regulatory pathways, and supplier relationships in distinct ways. In the Americas, procurement models and large immunization programs create demand for devices that balance unit efficiency with safety, and there is growing traction for connected devices that can integrate with immunization registries and electronic medical records. This region also exhibits accelerated conversations about nearshoring and manufacturing scale-up to buffer against global supply interruptions.

Across Europe, Middle East & Africa, regulatory convergence and emphasis on patient safety drive interest in safety-engineered syringes and needle-free alternatives, while divergent procurement capacities produce a spectrum of adoption rates and device preferences. In high-income markets within this region, digital integration and lifecycle service offerings are becoming differentiators, whereas in resource-constrained settings the emphasis remains on simplicity, robustness, and cold chain efficiency.

Asia-Pacific presents a heterogeneous mix of rapid industrial capability, domestic manufacturing ambitions, and varied regulatory regimes. Several markets in this region are scaling local production capacity for both devices and formulation fill-finish, and there is strong interest in cost-effective disposable platforms as well as innovative needle-free technologies that can support mass immunization campaigns. Across all regions, differences in clinical practice, reimbursement models, and supply chain architecture mean that a one-size-fits-all device strategy is unlikely to succeed; instead, regionalized product adaptations and partnerships are needed to achieve both clinical and commercial objectives.

How corporate platform strategies, strategic alliances, regulatory positioning, and service models are redefining competitive advantage among device manufacturers

The competitive and collaborative behavior of key companies is shaping the evolution of vaccine delivery devices in several predictable ways. Leading manufacturers are investing in platform strategies that allow them to extend device functionality across multiple therapeutic areas while amortizing development and regulatory costs. Partnerships between device firms and biologics developers are increasingly common, reflecting the need to validate device-drug compatibility early in development and to design integrated patient support programs.

Supply-side consolidation and strategic alliances are visible where sterilization capacity, component supply, and high-volume assembly create barriers to rapid scaling. At the same time, smaller innovators are driving niche advances in needle-free technologies, micro-dosing, and digital adherence tools that incumbents may choose to acquire or integrate through licensing. Regulatory approvals and clearance pathways remain central competitive battlegrounds, and companies that demonstrate robust human factors testing, cybersecurity assurances, and post-market evidence generation can more readily secure health-system adoption.

Service models-ranging from device-as-a-service to full lifecycle support contracts that include training, maintenance, and data analytics-are emerging as differentiators that influence procurement decisions. Companies that are able to couple product quality with dependable supply and responsive service will command stronger positioning, particularly in markets where operational continuity and clinical outcomes are closely scrutinized.

Practical strategic moves for device manufacturers and health providers to enhance resilience, accelerate adoption, and capture sustained value across care settings

Industry leaders should adopt a multi-pronged strategy that balances short-term resilience with long-term innovation. First, diversify supplier portfolios and invest in dual-sourcing for critical components while evaluating nearshoring opportunities to reduce exposure to tariff volatility and logistic disruption. Second, prioritize modular product platforms that allow rapid reconfiguration between disposable and reusable elements, and design for interoperability with digital health ecosystems to extend clinical value.

Third, embed regulatory strategy and human factors engineering early in the development lifecycle to reduce time-to-adoption risk and to support clear labeling and post-market surveillance plans. Fourth, pursue partnerships with formulation developers to ensure device-drug compatibility is optimized for both liquid and lyophilized presentations, and adapt device interfaces to the practical needs of primary care, specialty clinics, hospitals, ambulatory centers, and home healthcare settings. Fifth, consider services that go beyond the device itself-training, maintenance, data analytics, and lifecycle management-to create differentiated procurement propositions that lower total cost of administration and improve clinical adherence.

Finally, embrace evidence generation that demonstrates real-world performance, safety, and user preference. Operational pilots, pragmatic usability studies, and registry data can accelerate payer and provider acceptance. By aligning product design with procurement realities and clinical workflows, industry leaders can reduce adoption friction and create durable pathways to scale.

Comprehensive mixed-methods research approach combining primary interviews, regulatory and patent review, supply chain mapping, and scenario analysis to validate insights

This research synthesizes diverse data streams to ensure robust, evidence-based conclusions. Primary research included structured interviews with device engineers, clinical leaders across hospital and ambulatory settings, procurement officers, and regulatory experts to capture experiential insights on device performance, usability, and supply constraints. Expert workshops and advisory panels informed interpretations of clinical workflows and the practical trade-offs clinicians face when selecting devices for different administration routes and product forms.

Secondary research encompassed public regulatory filings, guidance documents, patent literature, manufacturer technical specifications, and peer-reviewed clinical studies to validate design claims and safety profiles. Supply chain mapping combined vendor disclosures, logistics data, and trade flow analysis to identify concentration risks and potential resiliency strategies. Where appropriate, human factors and usability testing reports were reviewed to assess user error risks and training needs.

Analytic approaches included cross-validation of qualitative findings with documentary evidence, scenario stress-testing of supply chain responses to tariff and disruption events, and thematic synthesis of technology adoption drivers. Care was taken to triangulate claims from manufacturers with independent clinical and procurement perspectives to deliver balanced, actionable insights. Limitations of the research were mitigated by seeking multiple sources for critical assertions and by documenting areas where data scarcity requires cautious interpretation.

Synthesis of strategic imperatives showing how technology, regulation, segmentation, and supply resilience must converge to enable effective vaccine delivery solutions

The vaccine delivery device landscape is undergoing a period of purposeful transformation driven by technological capability, regulatory evolution, and heightened expectations around safety and supply resilience. Device innovation is increasingly judged by its ability to deliver measurable improvements in clinical workflows, adherence, and total system reliability rather than by discrete product features alone. Supply chain and trade dynamics have accelerated strategic shifts such as diversification of suppliers, modular manufacturing approaches, and a renewed emphasis on localized capacity where it delivers operational advantages.

Segmentation across device types, administration routes, end-user settings, and formulation formats remains essential for matching solution attributes to practical use cases. Regional differences underscore the need for adaptable strategies that consider procurement mechanisms, regulatory regimes, and infrastructure constraints. Companies that marry robust product engineering with thoughtful regulatory planning, service-oriented business models, and targeted evidence generation will be best positioned to secure durable adoption. The path forward requires coordinated action across design, manufacturing, and commercial functions to translate promising technologies into sustainable improvements in vaccine delivery and public health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising clinical adoption of needle-free jet injectors and microarray patch systems to improve patient compliance and reduce disposal hazards
  • 5.2. Integration of IoT-enabled smart autoinjectors for real-time dosage tracking and remote patient monitoring during mass vaccination
  • 5.3. Development of thermostable vaccine delivery devices eliminating cold chain requirements for distribution in low-resource regions
  • 5.4. Advances in dissolvable microneedle patch technology enabling self-administered, pain-free vaccination outside clinical settings
  • 5.5. Emergence of combination vaccine auto-disable syringes designed to minimize multi-dose cross-contamination and streamline immunization programs
  • 5.6. Scaling modular and prefabricated filling and finishing platforms to accelerate vaccine manufacturing response during pandemics
  • 5.7. Adoption of biodegradable and single-use eco-friendly syringe materials addressing sustainability and biohazard management concerns
  • 5.8. Regulatory alignment initiatives harmonizing global approval pathways for innovative vaccine delivery devices and digital health integrations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Delivery Devices Market, by Device Type

  • 8.1. Auto-Injectors
    • 8.1.1. Disposable Auto-Injectors
    • 8.1.2. Electronic Reusable Auto-Injectors
    • 8.1.3. Mechanical Reusable Auto-Injectors
  • 8.2. Infusion Pumps
    • 8.2.1. Elastomeric Pumps
    • 8.2.2. Syringe Pumps
    • 8.2.3. Volumetric Pumps
      • 8.2.3.1. Ambulatory Volumetric Pumps
      • 8.2.3.2. Floor-Mounted Volumetric Pumps
  • 8.3. Jet Injectors
    • 8.3.1. Multi-Use Nozzle Jet Injectors
    • 8.3.2. Single-Use Nozzle Jet Injectors
  • 8.4. Needle-Free Injectors
    • 8.4.1. Liquid Injectors
      • 8.4.1.1. Electric Liquid Injectors
      • 8.4.1.2. Gas-Based Liquid Injectors
      • 8.4.1.3. Spring-Based Liquid Injectors
    • 8.4.2. Powder Injectors
  • 8.5. Pen Injectors
    • 8.5.1. Disposable Pen Injectors
    • 8.5.2. Reusable Pen Injectors
      • 8.5.2.1. Electronic Reusable Pen Injectors
      • 8.5.2.2. Mechanical Reusable Pen Injectors
  • 8.6. Prefilled Syringes
    • 8.6.1. Glass Prefilled Syringes
    • 8.6.2. Plastic Prefilled Syringes
      • 8.6.2.1. External Needle Prefilled Syringes
      • 8.6.2.2. Integrated Needle Prefilled Syringes
  • 8.7. Safety Syringes
    • 8.7.1. Active Safety Syringes
    • 8.7.2. Passive Safety Syringes

9. Vaccine Delivery Devices Market, by Administration Route

  • 9.1. Intradermal Injection
  • 9.2. Intramuscular Injection
  • 9.3. Intravenous Injection
  • 9.4. Mucosal Delivery
    • 9.4.1. Nasal Delivery
    • 9.4.2. Oral Delivery
  • 9.5. Subcutaneous Injection

10. Vaccine Delivery Devices Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Clinics
    • 10.2.1. Primary Care Clinics
    • 10.2.2. Specialty Clinics
  • 10.3. Home Healthcare
  • 10.4. Hospitals

11. Vaccine Delivery Devices Market, by Product Form

  • 11.1. Liquid Formulations
    • 11.1.1. Multi-Dose Vials
    • 11.1.2. Single-Dose Vials
  • 11.2. Lyophilized Formulations
    • 11.2.1. Multi-Dose Vials
    • 11.2.2. Single-Dose Vials

12. Vaccine Delivery Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vaccine Delivery Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vaccine Delivery Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. West Pharmaceutical Services, Inc.
    • 15.3.2. Becton, Dickinson and Company
    • 15.3.3. SCHOTT AG
    • 15.3.4. Gerresheimer AG
    • 15.3.5. Stevanato Group S.p.A.
    • 15.3.6. Terumo Corporation
    • 15.3.7. Nipro Corporation
    • 15.3.8. Catalent, Inc.
    • 15.3.9. Vetter Pharma International GmbH
    • 15.3.10. Recipharm AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. VACCINE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. VACCINE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VACCINE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MULTI-USE NOZZLE JET INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MULTI-USE NOZZLE JET INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MULTI-USE NOZZLE JET INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MULTI-USE NOZZLE JET INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MULTI-USE NOZZLE JET INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MULTI-USE NOZZLE JET INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SINGLE-USE NOZZLE JET INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SINGLE-USE NOZZLE JET INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SINGLE-USE NOZZLE JET INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SINGLE-USE NOZZLE JET INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SINGLE-USE NOZZLE JET INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SINGLE-USE NOZZLE JET INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRIC LIQUID INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRIC LIQUID INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRIC LIQUID INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRIC LIQUID INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRIC LIQUID INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRIC LIQUID INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GAS-BASED LIQUID INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GAS-BASED LIQUID INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GAS-BASED LIQUID INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GAS-BASED LIQUID INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GAS-BASED LIQUID INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GAS-BASED LIQUID INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPRING-BASED LIQUID INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPRING-BASED LIQUID INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPRING-BASED LIQUID INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPRING-BASED LIQUID INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPRING-BASED LIQUID INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPRING-BASED LIQUID INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GLASS PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GLASS PREFILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GLASS PREFILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GLASS PREFILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GLASS PREFILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GLASS PREFILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PLASTIC PREFILLED SYRINGES, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PLASTIC PREFILLED SYRINGES, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PLASTIC PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PLASTIC PREFILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PLASTIC PREFILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PLASTIC PREFILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PLASTIC PREFILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PLASTIC PREFILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY EXTERNAL NEEDLE PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY EXTERNAL NEEDLE PREFILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY EXTERNAL NEEDLE PREFILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY EXTERNAL NEEDLE PREFILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY EXTERNAL NEEDLE PREFILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY EXTERNAL NEEDLE PREFILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTEGRATED NEEDLE PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTEGRATED NEEDLE PREFILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTEGRATED NEEDLE PREFILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTEGRATED NEEDLE PREFILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTEGRATED NEEDLE PREFILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTEGRATED NEEDLE PREFILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ACTIVE SAFETY SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ACTIVE SAFETY SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ACTIVE SAFETY SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ACTIVE SAFETY SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ACTIVE SAFETY SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ACTIVE SAFETY SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PASSIVE SAFETY SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PASSIVE SAFETY SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PASSIVE SAFETY SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PASSIVE SAFETY SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PASSIVE SAFETY SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PASSIVE SAFETY SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VACCINE DELIVERY DE